AR039017A1 - Material micronizado cristalino, procedimiento para su preparacion y su utilizacion para la preparacion de un medicamento - Google Patents

Material micronizado cristalino, procedimiento para su preparacion y su utilizacion para la preparacion de un medicamento

Info

Publication number
AR039017A1
AR039017A1 ARP030100957A ARP030100957A AR039017A1 AR 039017 A1 AR039017 A1 AR 039017A1 AR P030100957 A ARP030100957 A AR P030100957A AR P030100957 A ARP030100957 A AR P030100957A AR 039017 A1 AR039017 A1 AR 039017A1
Authority
AR
Argentina
Prior art keywords
preparation
beta
procedure
medicinal product
crystalline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Suspension/Interruption
Application number
ARP030100957A
Other languages
English (en)
Inventor
Graebner Hagen Dr
Trunk Michael Dr
Walz Michael Dr
Bender Helmut Dr
Konrad Schindler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Pharma GmbH Co KG
Original Assignee
Boehringer Ingelheim Pharma GmbH Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27797948&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR039017(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Pharma GmbH Co KG filed Critical Boehringer Ingelheim Pharma GmbH Co KG
Publication of AR039017A1 publication Critical patent/AR039017A1/es
Suspension/Interruption legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C07D451/06—Oxygen atoms
    • C07D451/10—Oxygen atoms acylated by aliphatic or araliphatic carboxylic acids, e.g. atropine, scopolamine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Catalysts (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Glass Compositions (AREA)
  • Silicates, Zeolites, And Molecular Sieves (AREA)
  • Medicinal Preparation (AREA)
  • Hybrid Cells (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Material micronizado cristalino de bromuro de (1alfa,2beta,4beta,5alfa,7beta)-7-[(hidroxi-di-2-tienil-acetil)oxi]-9,9-dimetil-3-oxa-9-azonia-triciclo-[3.3.1.02,4]nonano, a procedimientos para su preparación así como a su utilización para la preparación de un medicamento, en particular para la preparación de un medicamento con efecto anticolinérgico. Reivindicación 1: Material micronizado de bromuro de tiotropio cristalino, caracterizado por un tamano de partículas X50 comprendido entre 1,0 micronm y 3,5 micronm a un valor de Q(5,8) mayor que 60 %, por un valor de la superficie específica situado en el intervalo comprendido entre 2m2/g y 5m2/g, por un calor específico de disolución mayor que 65 Ws/g, así como por un contenido en agua de aproximadamente 1 % a aproximadamente 4,5 %.
ARP030100957A 2002-03-20 2003-03-19 Material micronizado cristalino, procedimiento para su preparacion y su utilizacion para la preparacion de un medicamento Suspension/Interruption AR039017A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10212264A DE10212264A1 (de) 2002-03-20 2002-03-20 Kristallines Mikronisat, Verfahren zu dessen Herstellung und dessen Verwendung zur Herstellung eines Arzneimittels

Publications (1)

Publication Number Publication Date
AR039017A1 true AR039017A1 (es) 2005-02-02

Family

ID=27797948

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030100957A Suspension/Interruption AR039017A1 (es) 2002-03-20 2003-03-19 Material micronizado cristalino, procedimiento para su preparacion y su utilizacion para la preparacion de un medicamento

Country Status (37)

Country Link
EP (3) EP3053921A1 (es)
JP (1) JP4331619B2 (es)
KR (2) KR101021430B1 (es)
CN (2) CN100368410C (es)
AR (1) AR039017A1 (es)
AT (1) ATE369365T1 (es)
AU (1) AU2003212327B2 (es)
BR (1) BRPI0308513B8 (es)
CA (1) CA2479652C (es)
CO (1) CO5611105A2 (es)
CY (2) CY1106923T1 (es)
DE (2) DE10212264A1 (es)
DK (2) DK1785422T3 (es)
EA (1) EA007064B1 (es)
EC (1) ECSP045310A (es)
ES (2) ES2291619T5 (es)
HK (1) HK1078871A1 (es)
HR (1) HRP20040855B1 (es)
HU (1) HUE031876T2 (es)
IL (2) IL163841A0 (es)
LT (1) LT1785422T (es)
ME (1) ME02764B (es)
MX (1) MXPA04009056A (es)
MY (1) MY139720A (es)
NO (2) NO346754B1 (es)
NZ (1) NZ535808A (es)
PE (1) PE20030838A1 (es)
PL (1) PL220730B1 (es)
PT (2) PT1487832E (es)
RS (1) RS57551B1 (es)
SA (1) SA03240098B1 (es)
SI (1) SI1487832T2 (es)
TW (1) TWI345975B (es)
UA (1) UA78295C2 (es)
UY (1) UY27725A1 (es)
WO (1) WO2003078429A1 (es)
ZA (1) ZA200405636B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7056916B2 (en) 2002-11-15 2006-06-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Medicaments for the treatment of chronic obstructive pulmonary disease
CN1875020B (zh) 2003-11-03 2010-04-28 贝林格尔.英格海姆国际有限公司 新颖的噻托铵盐,其制备方法及其药物制剂
WO2005042526A1 (de) 2003-11-03 2005-05-12 Boehringer Ingelheim International Gmbh Verfahren zur herstellung von tiotropiumsalze, tiotropiumsalze sowie arzneimitte lformulierungen diese enthaltend
US7220742B2 (en) 2004-05-14 2007-05-22 Boehringer Ingelheim International Gmbh Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments
DE102004024451A1 (de) 2004-05-14 2005-12-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pulverformulierungen für die Inhalation, die Enantiomerenreine Betaagonisten enthalten
RU2007144531A (ru) * 2005-05-02 2009-06-10 БЕРИНГЕР ИНГЕЛЬХАЙМ ИНТЕРНАЦИОНАЛЬ ГмбХ (DE) Новые кристаллические формы тиотропийбромида
CA2606549A1 (en) 2005-05-02 2006-11-09 Boehringer Ingelheim International Gmbh Crystalline forms of tiotropium bromide
AU2006281449B2 (en) 2005-08-15 2013-01-31 Boehringer Ingelheim International Gmbh Method for producing betamimetics
US20070086957A1 (en) * 2005-10-10 2007-04-19 Thierry Bouyssou Combination of medicaments for the treatment of respiratory diseases
DE102005059602A1 (de) * 2005-12-14 2007-06-21 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Mikronisierung
US9108962B2 (en) 2005-12-19 2015-08-18 Sicor, Inc. Forms of tiotropium bromide and processes for preparation thereof
JP5086267B2 (ja) 2005-12-19 2012-11-28 シコール インコーポレイティド 臭化チオトロピウムの新規な形態およびそれを製造する方法
CN100999521B (zh) * 2006-01-13 2010-12-08 江苏正大天晴药业股份有限公司 结晶性抗胆碱药噻托溴铵
GB0716026D0 (en) 2007-08-16 2007-09-26 Norton Healthcare Ltd An inhalable medicament
WO2011093815A2 (en) * 2010-01-29 2011-08-04 Mahmut Bilgic Pharmaceutical compositions comprising formoterol and mometasone
GB201200525D0 (en) 2011-12-19 2012-02-29 Teva Branded Pharmaceutical Prod R & D Inc An inhalable medicament
PT106142B (pt) * 2012-02-10 2014-07-18 Hovione Farmaci Ncia S A Processo para a preparação de brometo de tiotrópio
US20150150802A1 (en) 2012-07-05 2015-06-04 Arven Ilac Sanayi Ve Ticaret Anonim Sirketi Dry powder inhaler compositions comprising long acting muscarinic antagonists
EP2705838A1 (en) * 2012-09-06 2014-03-12 Xspray Microparticles Ab Tiotropium preparations
WO2014042605A1 (en) * 2012-09-11 2014-03-20 Mahmut Bilgic New tiotropium bromide crystalline form
US10034866B2 (en) 2014-06-19 2018-07-31 Teva Branded Pharmaceutical Products R&D, Inc. Inhalable medicament comprising tiotropium
UA115958C2 (uk) 2014-09-09 2018-01-10 Вектура Лімітед Препарат, що містить глікопіролат, спосіб та пристрій
WO2017068119A1 (en) * 2015-10-23 2017-04-27 Arven Ilac Sanayi Ve Ticaret A.S. Blister for tiotropium bromide inhalable formulation
CA3002300A1 (en) * 2015-10-23 2017-04-27 Arven Ilac Sanayi Ve Ticaret A.S. Blister for inhalable formulation of tiotropium bromide
CN115737610B (zh) * 2021-12-13 2024-02-27 苏州欧米尼医药有限公司 一种噻托溴铵吸入粉雾剂及其活性成分的气流粉碎方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4570630A (en) 1983-08-03 1986-02-18 Miles Laboratories, Inc. Medicament inhalation device
PH26882A (en) 1985-07-30 1992-11-16 Glaxo Group Ltd Devices for administering medicaments to patients
DE3931041C2 (de) * 1989-09-16 2000-04-06 Boehringer Ingelheim Kg Ester von Thienylcarbonsäuren mit Aminoalkoholen, ihre Quaternierungsprodukte, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel
US5610163A (en) 1989-09-16 1997-03-11 Boehringer Ingelheim Gmbh Esters of thienyl carboxylic acids and amino alcohols and their quaternization products
SE9302777D0 (sv) 1993-08-27 1993-08-27 Astra Ab Process for conditioning substances
US5874063A (en) 1991-04-11 1999-02-23 Astra Aktiebolag Pharmaceutical formulation
DE4318455A1 (de) 1993-06-03 1994-12-08 Boehringer Ingelheim Kg Kapselhalterung
DE19515625C2 (de) * 1995-04-28 1998-02-19 Boehringer Ingelheim Kg Verfahren zur Herstellung von enantiomerenreinen Tropasäureestern
FR2779347A1 (fr) * 1998-06-05 1999-12-03 Arlette Guerry Procede de micronisation de substances medicamenteuses
ATE234604T1 (de) 1998-08-04 2003-04-15 Jago Res Ag Medizinische aerosolformulierungen
EP1283036B2 (de) * 1998-11-13 2020-01-01 Jagotec AG Multidosis-Trockenpulverinhalator mit Pulverreservoir
GB9902689D0 (en) * 1999-02-08 1999-03-31 Novartis Ag Organic compounds
DE19921693A1 (de) 1999-05-12 2000-11-16 Boehringer Ingelheim Pharma Neuartige Arzneimittelkompositionen auf der Basis von anticholinergisch wirksamen Verbindungen und ß-Mimetika
CA2371046A1 (en) † 1999-04-23 2000-11-02 Eugene Lukanidin Therapeutic compositions and methods for enhancing angiogenesis
AU7685200A (en) 1999-10-12 2001-04-23 Kaken Pharmaceutical Co., Ltd. Powdery inhalational preparations and process for producing the same
UA72014C2 (en) 2000-10-12 2005-01-17 Boehringer Ingelheim Pharma Tiotropium-containing powdery preparations for inhalations intended for treating asthma and chronic obstructive pulmonary disease (variants), method for their production and capsule
DK1326862T3 (da) 2000-10-12 2004-11-22 Boehringer Ingelheim Pharma Krystallinsk monohydrat af tiotropiumbromid, fremgangsmåde til fremstilling deraf og anvendelse deraf til fremstilling af et lægemiddel
DE10126924A1 (de) 2001-06-01 2002-12-05 Boehringer Ingelheim Pharma Inhalationskapseln
KR100971616B1 (ko) 2001-06-22 2010-07-22 베링거 잉겔하임 파르마 게엠베하 운트 코 카게 결정질 항콜린제, 이의 제조방법 및 이를 포함하는 약제학적 조성물
US7309707B2 (en) 2002-03-20 2007-12-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Crystalline micronisate, process for the manufacture thereof and use thereof for the preparation of a medicament
US7244842B2 (en) 2002-11-15 2007-07-17 Orchid Chemicals & Pharmaceuticals Ltd. Amorphous hydrate of a cephalosporin antibiotic
DE102005059602A1 (de) 2005-12-14 2007-06-21 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Mikronisierung
CN102127069A (zh) 2010-01-20 2011-07-20 鲁南制药集团股份有限公司 噻托溴铵晶体

Also Published As

Publication number Publication date
ES2291619T5 (es) 2018-12-07
HK1078871A1 (en) 2006-03-24
DE50307883D1 (de) 2007-09-20
PT1785422T (pt) 2017-02-17
CY1106923T1 (el) 2012-09-26
CA2479652A1 (en) 2003-09-25
SI1487832T2 (sl) 2018-11-30
ES2291619T3 (es) 2008-03-01
DK1487832T4 (en) 2018-12-10
IL163841A0 (en) 2005-12-18
LT1785422T (lt) 2017-02-10
ATE369365T1 (de) 2007-08-15
EP1785422B1 (de) 2016-11-16
JP2005526776A (ja) 2005-09-08
ES2615460T3 (es) 2017-06-07
EP1487832B9 (de) 2019-01-23
CN1642952A (zh) 2005-07-20
EP1785422A8 (de) 2010-06-23
MY139720A (en) 2009-10-30
HUE031876T2 (en) 2017-08-28
BRPI0308513B1 (pt) 2016-04-19
SA03240098B1 (ar) 2008-03-24
NO20044003L (no) 2004-10-14
EP1487832A1 (de) 2004-12-22
PT1487832E (pt) 2007-08-27
PL371799A1 (en) 2005-06-27
EP1487832B1 (de) 2007-08-08
PE20030838A1 (es) 2003-11-21
AU2003212327A1 (en) 2003-09-29
EP1785422A1 (de) 2007-05-16
NO346754B1 (no) 2022-12-12
HRP20040855B1 (en) 2012-11-30
AU2003212327B2 (en) 2009-02-05
ECSP045310A (es) 2004-10-26
EP3053921A1 (de) 2016-08-10
TWI345975B (en) 2011-08-01
NO344427B1 (no) 2019-12-02
ZA200405636B (en) 2006-01-25
CY1118855T1 (el) 2018-01-10
UA78295C2 (en) 2007-03-15
CO5611105A2 (es) 2006-02-28
IL163841A (en) 2015-10-29
SI1487832T1 (sl) 2007-12-31
MXPA04009056A (es) 2005-01-25
KR101094091B1 (ko) 2011-12-15
JP4331619B2 (ja) 2009-09-16
BRPI0308513B8 (pt) 2021-05-25
CA2479652C (en) 2012-07-10
ME02764B (me) 2011-05-10
NO20190824A1 (no) 2004-10-14
PL220730B1 (pl) 2015-12-31
WO2003078429A1 (de) 2003-09-25
BR0308513A (pt) 2005-01-04
DE10212264A1 (de) 2003-10-02
KR20100135983A (ko) 2010-12-27
KR101021430B1 (ko) 2011-03-15
DK1487832T3 (da) 2007-11-05
EA007064B1 (ru) 2006-06-30
DK1785422T3 (en) 2017-02-27
UY27725A1 (es) 2003-10-31
RS57551B1 (sr) 2018-10-31
TW200305421A (en) 2003-11-01
MEP46708A (en) 2011-02-10
EP1487832B2 (de) 2018-08-29
HRP20040855A2 (en) 2005-06-30
EA200401142A1 (ru) 2005-04-28
KR20050008662A (ko) 2005-01-21
CN100368410C (zh) 2008-02-13
CN101220025A (zh) 2008-07-16
NZ535808A (en) 2005-09-30

Similar Documents

Publication Publication Date Title
AR039017A1 (es) Material micronizado cristalino, procedimiento para su preparacion y su utilizacion para la preparacion de un medicamento
AR034389A1 (es) Monohidrato cristalino de bromuro de tiotropio, procedimiento para su preparacion, su utilización para la preparacion de un medicamento, un medicamento que lo contiene, los hidratos cristalinos del bromuro de tiotropio y un procedimiento para preparacion de estos hidratos cristalinos
UY29825A1 (es) Derivados sustituidos de 3h-imidazol-(4,5 b (beta))piridina-2-il benzoatos y benzamidas, composiciones farmacéuticas que los contienen y aplicaciones
MX2014001101A (es) Composiciones orales que contienen un ester 17-hydroxyprogesterona y metodos relacionados.
WO2012079092A3 (en) Testosterone undecanoate compositions
AR056609A1 (es) Composiciones estabilizadas de carbonato de lantano
PH12017502416A1 (en) 17-hydroxyprogesterone ester-containing oral compositions and related methods
HRP20220902T3 (hr) Pripravci i njihova upotreba u liječenju multiple skleroze
AR081575A1 (es) Formas de dosificacion oral de bendamustina y su uso terapeutico
PE20040121A1 (es) Formulaciones farmaceuticas de liberacion controlada del 5,8,14-triazatetraciclo [10.3.1.02,11.04.9]-hexadeca-2-(11),3,5,7,9-pentaeno
AR034518A1 (es) Incremento en la administracion transdermica de un farmaco
CO5261517A1 (es) Composiciones farmaceuticas analgesicas que contienen buprenorfina/naloxona, buprenorfina/naltrexona o buprenorfina/nalmefen en bajas dosis
AR020803A1 (es) Una composicion que comprende fexofenadina o una sal farmaceuticamente aceptable de la misma y el uso de la misma para la manufactura de unmedicamento
GT201300144A (es) Composiciones farmaceuticas
RS52777B (en) CURRENT RELEASE THERAPY SYSTEM FOR IMPROVED ORAL ABSORPTION 7 - [(E) -TERT-BUTYLOXYIMINOMETHYL] CAMPTOTECIN
CL2010000524A1 (es) Uso de una composición tópica que comprende 3,75% de imiquimod y un portador farmacéuticamente aceptable para preparar un medicamento útil para tratar verrugas genitales o perianales.
PE20151543A1 (es) Composicion farmaceutica oral de sales sulfato para comprimidos de uso dual y metodos para su uso
AR065816A1 (es) Regimen anticonceptivo oral
JP2015522025A5 (es)
CO5540295A2 (es) Comprimido para tragar que comprende paracetamol
AR065582A1 (es) Mejoras en composiciones medicinales o relativas a las mismas
AR045263A1 (es) Metodo, kit y composicion farmaceutica para tratar infecciones virales
BR0008057A (pt) Forma cristalina de eplerenona apresentando velocidade de dissolução intensificada
CO5640085A2 (es) Formulaciones farmaceuticas que comprenden amoxicilina y clavulanato
PE20030646A1 (es) Medicamentos para la inhalacion que comprenden sales de tiotropio y salmeterol

Legal Events

Date Code Title Description
FB Suspension of granting procedure